According to GeekWire, Mozart Therapeutics has secured $55 million in Series A funding. The round was led by ARCH Venture Partners along with Sofinnova Partners. Other backers include MRL Ventures Fund from Merck, Leaps by Bayer, and Eli Lilly & Company.

Altitude Life Science Ventures and Alexandria Venture Investments were additional investors in the round, and the company received seed funding from ARCH.

Founded on seminal work from leading scientists, Mozart is developing biologics to target a novel T cell network of pathogenic CD4 and cytolytic-regulatory CD8 T cells.